{
  "id": "a2c9232e8dbad9d95e93ab8c369886981cd26773",
  "url": "https://www.r-bloggers.com/2023/11/pfizer-leaders-discuss-the-adoption-of-open-source-predominantly-r-in-clinical-trial-reporting/",
  "created_at_utc": "2025-11-17T20:39:19Z",
  "data": null,
  "raw_original": {
    "uuid": "e14efecc-d8c0-452c-8c43-15a3189855a1",
    "created_at": "2025-11-17 20:39:19",
    "raw_json": {
      "article_author": null,
      "article_headline": null,
      "article_modified": null,
      "article_published": null,
      "article_section": null,
      "article_tags": null,
      "canonical_url": "https://www.r-bloggers.com/2023/11/pfizer-leaders-discuss-the-adoption-of-open-source-predominantly-r-in-clinical-trial-reporting/",
      "crawled_at": "2025-11-17T09:57:52.448002",
      "external_links": [
        {
          "href": "https://www.r-consortium.org/blog/2023/11/09/pfizer-leaders-discuss-the-adoption-of-open-source-predominantly-r-in-clinical-trial-reporting",
          "text": "R Consortium"
        },
        {
          "href": "http://r-posts.com/",
          "text": "here"
        },
        {
          "href": "https://phuse.global/",
          "text": "PHUSE"
        },
        {
          "href": "https://www.pfizer.com/",
          "text": "Pfizer"
        },
        {
          "href": "https://www.linkedin.com/in/michaelrimler",
          "text": "Michael Rimler"
        },
        {
          "href": "https://uk.linkedin.com/in/mikeksmith",
          "text": "Mike Smith"
        },
        {
          "href": "https://www.linkedin.com/in/patti-compton-90b510",
          "text": "Patti Compton"
        },
        {
          "href": "https://www.youtube.com/watch?v=CHEAVlGJYKg",
          "text": "here"
        },
        {
          "href": "https://www.r-consortium.org/blog/2023/11/09/pfizer-leaders-discuss-the-adoption-of-open-source-predominantly-r-in-clinical-trial-reporting",
          "text": "Pfizer Leaders Discuss the Adoption of Open Source, Predominantly R, in Clinical Trial Reporting"
        },
        {
          "href": "https://www.r-consortium.org/",
          "text": "R Consortium"
        },
        {
          "href": "https://www.r-consortium.org/blog/2023/11/09/pfizer-leaders-discuss-the-adoption-of-open-source-predominantly-r-in-clinical-trial-reporting",
          "text": "R Consortium"
        },
        {
          "href": "https://feedburner.google.com/fb/a/mailverify?uri=RBloggers",
          "text": "daily e-mail updates"
        },
        {
          "href": "https://www.r-project.org/",
          "text": "R"
        },
        {
          "href": "https://www.r-users.com/",
          "text": "Click here if you're looking to post or find an R/data-science job"
        },
        {
          "href": "http://r-posts.com/",
          "text": "here"
        }
      ],
      "h1_title": "R-bloggers",
      "html_title": "Pfizer Leaders Discuss the Adoption of Open Source, Predominantly R, in Clinical Trial Reporting | R-bloggers",
      "images": [
        {
          "alt": null,
          "base64": "data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7",
          "src": "https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif"
        },
        {
          "alt": null,
          "base64": null,
          "src": "https://lh7-us.googleusercontent.com/nEGVIMvntK8zmG5LKuvW9Wut-Bi_kLbBVOHPO5enGGXuFr2zl1yCvMxQt4Qkgevzik8YxdVdKijPScCM1mi4G2OybXwzvZSgYw-y3CKRIbNUJHTWIyQtQINPh4GYHsDxh2K236vQ-DIu8CNlS5osl4M"
        }
      ],
      "internal_links": [
        {
          "href": "https://www.r-bloggers.com/author/r-consortium/",
          "text": "R Consortium"
        },
        {
          "href": "https://www.r-bloggers.com/category/r-bloggers/",
          "text": "R bloggers"
        },
        {
          "href": "https://www.r-bloggers.com/",
          "text": "R-bloggers"
        },
        {
          "href": "https://www.r-bloggers.com/contact-us/",
          "text": "here"
        },
        {
          "href": "https://www.r-bloggers.com/add-your-blog/",
          "text": "click here"
        },
        {
          "href": "https://www.r-bloggers.com/",
          "text": "R-bloggers.com"
        },
        {
          "href": "https://www.r-bloggers.com/how-to-learn-r-2/",
          "text": "learning R"
        },
        {
          "href": "https://www.r-bloggers.com/add-your-blog/",
          "text": "click here"
        }
      ],
      "lang": "en-US",
      "main_html": "<article class=\"post-379822 post type-post status-publish format-standard hentry category-r-bloggers\">\n<header class=\"post-header\">\n<h1 class=\"entry-title\">Pfizer Leaders Discuss the Adoption of Open Source, Predominantly R, in Clinical Trial Reporting</h1>\n<p class=\"meta post-meta\">Posted on <span class=\"updated\">November 9, 2023</span>  by <span class=\"vcard author\"><a class=\"fn\" href=\"https://www.r-bloggers.com/author/r-consortium/\">R Consortium</a></span>  in <a href=\"https://www.r-bloggers.com/category/r-bloggers/\" rel=\"category tag\">R bloggers</a> | 0 Comments</p>\n</header>\n<div class=\"entry clearfix\">\n<!-- \r\n<div style=\"min-height: 30px;\">\r\n[social4i size=\"small\" align=\"align-left\"]\r\n</div>\r\n-->\n<div style=\"border: 1px solid; background: none repeat scroll 0 0 #EDEDED; margin: 1px; font-size: 12px;\">\r\n[This article was first published on  <strong><a href=\"https://www.r-consortium.org/blog/2023/11/09/pfizer-leaders-discuss-the-adoption-of-open-source-predominantly-r-in-clinical-trial-reporting\"> R Consortium</a></strong>, and kindly contributed to <a href=\"https://www.r-bloggers.com/\" rel=\"nofollow\">R-bloggers</a>].  (You can report issue about the content on this page <a href=\"https://www.r-bloggers.com/contact-us/\">here</a>)\r\n<hr/>Want to share your content on R-bloggers?<a href=\"https://www.r-bloggers.com/add-your-blog/\" rel=\"nofollow\"> click here</a> if you have a blog, or <a href=\"http://r-posts.com/\" rel=\"nofollow\"> here</a> if you don't.\r\n</div>\n\n<!-- Share buttons by mashshare.net - Version: 3.8.9-->\n<figure class=\"wp-block-image\"><img alt=\"\" data-lazy-src=\"https://lh7-us.googleusercontent.com/nEGVIMvntK8zmG5LKuvW9Wut-Bi_kLbBVOHPO5enGGXuFr2zl1yCvMxQt4Qkgevzik8YxdVdKijPScCM1mi4G2OybXwzvZSgYw-y3CKRIbNUJHTWIyQtQINPh4GYHsDxh2K236vQ-DIu8CNlS5osl4M\" decoding=\"async\" src=\"https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif\"/><noscript><img alt=\"\" decoding=\"async\" src=\"https://lh7-us.googleusercontent.com/nEGVIMvntK8zmG5LKuvW9Wut-Bi_kLbBVOHPO5enGGXuFr2zl1yCvMxQt4Qkgevzik8YxdVdKijPScCM1mi4G2OybXwzvZSgYw-y3CKRIbNUJHTWIyQtQINPh4GYHsDxh2K236vQ-DIu8CNlS5osl4M\"/></noscript></figure>\n<p>In this <a href=\"https://phuse.global/\" rel=\"nofollow\" target=\"_blank\">PHUSE </a>video interview, <a href=\"https://www.pfizer.com/\" rel=\"nofollow\" target=\"_blank\">Pfizer</a> is making strides in incorporating open source tools into its clinical reporting processes. <a href=\"https://www.linkedin.com/in/michaelrimler\" rel=\"nofollow\" target=\"_blank\">Michael Rimler</a>, PHUSE Open Source Technologies Director, brings in <a href=\"https://uk.linkedin.com/in/mikeksmith\" rel=\"nofollow\" target=\"_blank\">Mike Smith</a>, Senior Director at Pfizer, head of its R Center of Excellence, and R Consortium board member, and <a href=\"https://www.linkedin.com/in/patti-compton-90b510\" rel=\"nofollow\" target=\"_blank\">Patti Compton</a>, Vice President and head of Statistical Data Science and Analytics at Pfizer, to discuss Pfizer’s open source journey. </p>\n<p>While Pfizer has used R for many years, primarily in clinical pharmacology and QA metrics, the company is now looking to transition more of its clinical trial reporting to be predominantly R based within the software development lifecycle. Smith notes some challenges of “changing the wheels on the bus while it’s rolling down the highway,” but both leaders emphasize the importance and benefits of collaboration through open source. </p>\n<p>Patti Compton sees opportunities to build Pfizer’s data science community, leverage the rich library ecosystem, and gain platform independence to take time out of drug development timelines. Both envision a future where submissions to regulators use interactive data tools to allow deeper exploration of clinical trial results.</p>\n<p>Smith predicts more interactive platforms between industry and regulators for activities like label negotiations within the next two to three years. Compton agrees that open source will be applied in new ways across drug discovery and development and expects expectations for data science skills to increase. The interview provides insight into Pfizer’s motivations and goals for advancing open source adoption within clinical reporting and analytics.</p>\n<p>You can watch the full interview <a href=\"https://www.youtube.com/watch?v=CHEAVlGJYKg\" rel=\"nofollow\" target=\"_blank\">here</a>.</p>\n<p>The post <a href=\"https://www.r-consortium.org/blog/2023/11/09/pfizer-leaders-discuss-the-adoption-of-open-source-predominantly-r-in-clinical-trial-reporting\" rel=\"nofollow\" target=\"_blank\">Pfizer Leaders Discuss the Adoption of Open Source, Predominantly R, in Clinical Trial Reporting</a> appeared first on <a href=\"https://www.r-consortium.org/\" rel=\"nofollow\" target=\"_blank\">R Consortium</a>.</p>\n<div class=\"jp-relatedposts\" id=\"jp-relatedposts\">\n<h3 class=\"jp-relatedposts-headline\"><em>Related</em></h3>\n</div>\n<!-- Share buttons by mashshare.net - Version: 3.8.9-->\n<div style=\"border: 1px solid; background: none repeat scroll 0 0 #EDEDED; margin: 1px; font-size: 13px;\">\n<div style=\"text-align: center;\">To <strong>leave a comment</strong> for the author, please follow the link and comment on their blog: <strong><a href=\"https://www.r-consortium.org/blog/2023/11/09/pfizer-leaders-discuss-the-adoption-of-open-source-predominantly-r-in-clinical-trial-reporting\"> R Consortium</a></strong>.</div>\n<hr>\n<a href=\"https://www.r-bloggers.com/\" rel=\"nofollow\">R-bloggers.com</a> offers <strong><a href=\"https://feedburner.google.com/fb/a/mailverify?uri=RBloggers\" rel=\"nofollow\">daily e-mail updates</a></strong> about <a href=\"https://www.r-project.org/\" rel=\"nofollow\" title=\"The R Project for Statistical Computing\">R</a> news and tutorials about <a href=\"https://www.r-bloggers.com/how-to-learn-r-2/\" rel=\"nofollow\" title=\"R tutorials\">learning R</a> and many other topics. <a href=\"https://www.r-users.com/\" rel=\"nofollow\" title=\"Data science jobs\">Click here if you're looking to post or find an R/data-science job</a>.\r\n\r\n<hr/>Want to share your content on R-bloggers?<a href=\"https://www.r-bloggers.com/add-your-blog/\" rel=\"nofollow\"> click here</a> if you have a blog, or <a href=\"http://r-posts.com/\" rel=\"nofollow\"> here</a> if you don't.\r\n</hr></div> </div>\n</article>",
      "main_text": "Pfizer Leaders Discuss the Adoption of Open Source, Predominantly R, in Clinical Trial Reporting\nPosted on\nNovember 9, 2023\nby\nR Consortium\nin\nR bloggers\n| 0 Comments\n[This article was first published on\nR Consortium\n, and kindly contributed to\nR-bloggers\n].  (You can report issue about the content on this page\nhere\n)\nWant to share your content on R-bloggers?\nclick here\nif you have a blog, or\nhere\nif you don't.\nIn this\nPHUSE\nvideo interview,\nPfizer\nis making strides in incorporating open source tools into its clinical reporting processes.\nMichael Rimler\n, PHUSE Open Source Technologies Director, brings in\nMike Smith\n, Senior Director at Pfizer, head of its R Center of Excellence, and R Consortium board member, and\nPatti Compton\n, Vice President and head of Statistical Data Science and Analytics at Pfizer, to discuss Pfizer’s open source journey.\nWhile Pfizer has used R for many years, primarily in clinical pharmacology and QA metrics, the company is now looking to transition more of its clinical trial reporting to be predominantly R based within the software development lifecycle. Smith notes some challenges of “changing the wheels on the bus while it’s rolling down the highway,” but both leaders emphasize the importance and benefits of collaboration through open source.\nPatti Compton sees opportunities to build Pfizer’s data science community, leverage the rich library ecosystem, and gain platform independence to take time out of drug development timelines. Both envision a future where submissions to regulators use interactive data tools to allow deeper exploration of clinical trial results.\nSmith predicts more interactive platforms between industry and regulators for activities like label negotiations within the next two to three years. Compton agrees that open source will be applied in new ways across drug discovery and development and expects expectations for data science skills to increase. The interview provides insight into Pfizer’s motivations and goals for advancing open source adoption within clinical reporting and analytics.\nYou can watch the full interview\nhere\n.\nThe post\nPfizer Leaders Discuss the Adoption of Open Source, Predominantly R, in Clinical Trial Reporting\nappeared first on\nR Consortium\n.\nRelated\nTo\nleave a comment\nfor the author, please follow the link and comment on their blog:\nR Consortium\n.\nR-bloggers.com\noffers\ndaily e-mail updates\nabout\nR\nnews and tutorials about\nlearning R\nand many other topics.\nClick here if you're looking to post or find an R/data-science job\n.\nWant to share your content on R-bloggers?\nclick here\nif you have a blog, or\nhere\nif you don't.",
      "meta_description": "In this PHUSE video interview, Pfizer is making strides in incorporating open source tools into its clinical reporting processes. Michael Rimler, PHUSE Open Source Technologies Director, brings in Mike Smith,... The post Pfizer Leaders Discuss the Adoption of Open Source, Predominantly R, in Clinical Trial Reporting appeared first on R Consortium.",
      "meta_keywords": null,
      "og_description": "In this PHUSE video interview, Pfizer is making strides in incorporating open source tools into its clinical reporting processes. Michael Rimler, PHUSE Open Source Technologies Director, brings in Mike Smith,... The post Pfizer Leaders Discuss the Adoption of Open Source, Predominantly R, in Clinical Trial Reporting appeared first on R Consortium.",
      "og_image": "https://lh7-us.googleusercontent.com/nEGVIMvntK8zmG5LKuvW9Wut-Bi_kLbBVOHPO5enGGXuFr2zl1yCvMxQt4Qkgevzik8YxdVdKijPScCM1mi4G2OybXwzvZSgYw-y3CKRIbNUJHTWIyQtQINPh4GYHsDxh2K236vQ-DIu8CNlS5osl4M",
      "og_title": "Pfizer Leaders Discuss the Adoption of Open Source, Predominantly R, in Clinical Trial Reporting | R-bloggers",
      "raw_jsonld_article": null,
      "reading_time_min": 2.1,
      "sitemap_lastmod": "2023-11-09T14:44:19+00:00",
      "twitter_description": "In this PHUSE video interview, Pfizer is making strides in incorporating open source tools into its clinical reporting processes. Michael Rimler, PHUSE Open Source Technologies Director, brings in Mike Smith,... The post Pfizer Leaders Discuss the Adoption of Open Source, Predominantly R, in Clinical Trial Reporting appeared first on R Consortium.",
      "twitter_title": "Pfizer Leaders Discuss the Adoption of Open Source, Predominantly R, in Clinical Trial Reporting | R-bloggers",
      "url": "https://www.r-bloggers.com/2023/11/pfizer-leaders-discuss-the-adoption-of-open-source-predominantly-r-in-clinical-trial-reporting/",
      "word_count": 427
    }
  }
}